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Introduction
In the guidelines on the diagnosis and management of stable ischaemic heart disease issued by the American Heart Association and its allied societies, noninvasive assessment of myocardial ischaemia is the first line investigation for patients with low or intermediate pretest probability of coronary artery disease. Exercise is a frequently used stressor in these tests. In addition to specified endpoints suggestive of ischaemia such as exerciseinduced chest pain and ST segment deviation, exerciseinduced premature ventricular complexes (EIPVCs) commonly occur. The prevalence of EIPVCs ranges from 7% in normal subjects to 54% in patients with cardiovascular disease. In regard to their prognostic significance, some studies reported an adverse prognosis associated with EIPVCs while others found benign outcomes.
These studies are difficult to interpret because they analyse different patient groups ranging from asymptomatic patients to patients with clinical heart disease such as heart failure and myocardial infarction. In addition, the majority of studies do not adjust for cardiovascular risk factors which can cause profound confounder bias. In order to guide clinicians on the management of EIPVCs in these patients, we performed a systematic review and metaanalysis on studies looking at the prognosis of EIPVCs, excluding unadjusted studies and stratified patients according to whether or not they have clinical heart disease.
Methods
A systematic literature search was conducted on Medline (1965 to October 2016) and Embase (1974 to October 2016) for articles that examined the prognostic significance of EIPVCs. Index terms used were 'Exercise' OR 'Treadmill' AND 'Ventricular' AND 'Arrhythmia' OR 'Premature Ventricular Complexes' OR 'Ectopic'. Further articles were obtained by handsearching the reference lists of the relevant papers. A separate search for conference abstracts and proceedings was conducted on Embase using its advanced search option. It was not possible to identify studies that had neither been published nor presented at a conference because, unlike controlled trials, a registry for observational studies does not exist. There was no language restriction in our search.
A protocol for the metaanalysis was predetermined. The inclusion criterion for the metaanalysis was any observational study that compared the incidence of major adverse cardiac events or all cause death in patients with EIPVCs to those without these arrhythmias. Exposure was simply the possession of EI PVCs during the exercise stage or recovery stage of an exercise test. Outcomes were all cause mortality, cardiac mortality and cardiovascular events, namely nonfatal myocardial infarction, angina, cardiac hospital admissions and cardiac arrest. When different outcomes were analysed in the metaanalysis, only the allcause mortality was used as an endpoint in the metaanalysis. We separately analysed asymptomatic patients without clinical heart disease and patients with symptomatic heart disease. Exclusion criteria were: (1) studies that did not adjust for cardiovascular risk factors, including age, gender, hypertension, diabetes; and (2) studies that reported zero endpoints in either group. Some studies examined exercise stage EIPVCs and recovery EIPVCs separately, for example, Frolkis et al and Dewey et al. For the purpose of the metaanalysis, the separate substudies were counted as separate analyses. Likewise, some studies separately analysed patient groups with different EIPVC frequencies. For the sake of this metaanalysis, these groups were also counted as different analyses. For example, in MorshediMeibodi's study, there were 399 patients with EIPVCs <0.22/min and 393 patients with EI PVCs >0.22/min. These substudies were counted as separate analyses. In Dewey's study, not only were the EIPVCs classified as exercise stage EIPVCs and recovery EIPVCs, they were also separated into frequent and nonfrequent EIPVCs. This study therefore generated four substudies for the metaanalysis.
Data extraction for metaanalysis
The full texts of the studies satisfying the inclusion criteria were obtained. For each study, the following data were extracted by the primary investigator: (1) clinical status: symptomatic status, presence of clinical heart disease; (2) patient characteristics: mean age, percentage male, percentage of patients with diabetes or hypertension, and proportion of patients with ischaemia detected on exercise test; (3) adjustment of confounders including age, gender, hypertension, diabetes, and ischaemia detected on exercise ECG; (4) followup data: study endpoints with their relative risks and 95% CIs, and length of follow up. Go to:
Statistical analysis
Pooled relative risk (RR) of primary endpoints and their 95% CIs were calculated using the random effects model. Metaregression was used to investigate if any continuous variable (eg, percentage male, percentage with diabetes or hypertension, proportion of patients with ischaemic exercise ECG, length of followup) was associated with study outcomes. Sensitivity analysis was also performed to see if any categorical study characteristic (eg, whether ischaemia on exercise test or left ventricular (LV) function was adjusted for, stage of exercise test at which EIPVCs occur) affected study endpoints. Studies that did not report specific data for a particular characteristic were excluded from the metaregression and sensitivity analysis of that particular variable. Heterogeneity among the studies was evaluated using the I2 statistic. Publication bias was assessed by Egger's regression asymmetry test. All statistics were performed on Comprehensive MetaAnalysis software V.2, Biostat, Englewood, USA. The PRISMA (Preferred Reporting Items for Systematic reviews and MetaAnalyses) guidelines for the reporting of metaanalysis of observational studies in epidemiology were followed.
Results
The search strategy returned 3906 articles. There were no nonEnglish articles identified. No relevant conference abstracts or proceedings were found. There were no potential conflicts of interest among the studies. Thirtythree articles were on the prognostic significance of EIPVC; 23 were excluded according to our exclusion criteria (see online supplementary table S1).
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Ten studies satisfied our inclusion criteria-four were on asymptomatic patients without clinical heart disease and six were on patients with symptomatic heart disease. In the asymptomatic without clinical heart disease group, MorshediMeibodi et al had two substudies separately analysing frequent and non frequent EIPVCs. This provided an extra analysis for this group, for example, a total of 5 analyses from 4 studies. On the other hand, in the group with symptomatic heart disease, Frolkis et al separately analysed exercise stage EIPVCs and recovery EIPVCs. Dewey et al did the same and went further by dividing them into frequent and nonfrequent EIPVCs. Therefore, we have 10 analyses from 6 studies in this group. Figure 1 shows the inclusion diagram for the metaanalysis. Table 1 lists all the studies that analysed asymptomatic patients without clinical evidence of heart disease, while table 2 shows all the studies of patients with symptomatic cardiac disease. A detailed description of each study is provided. Table 1 Summary of all studies with asymptomatic patients without clinical heart disease included in the metaanalysis Table 2 Summary of all studies that included patients with clinical heart disease used in the metaanalysis Figure 1 Inclusion diagram for metaanalysis. EIPVC, exerciseinduced premature ventricular complexes. In asymptomatic patients who had no clinical evidence of heart disease, EIPVCs were associated with a pooled RR of 1.82 (95% CI 1.44 to 2.30) of developing cardiovascular events (including nonfatal myocardial infarction, angina, cardiac hospital admissions, cardiac arrest), cardiovascular mortality and all cause mortality over a mean followup of 16 years. In patients with symptomatic heart disease, the corresponding pooled RR was 1.36 (95% CI 1.18 to 1.57) over a mean followup of 5.4 years. Figure 2 summarises the results as Forrest plots.
Figure 2
Forrest plots of studies stratified by whether or not patients have clinical heart disease.
Description of the studies and quality assessment
There were four studies and five analyses in this group.
They were all observational prospective cohort studies. The total number of patients studied was 1239, totalling 20150 patientyears of followup. The mean age was 47 years, and the mean sample size was 249 with an average male preponderance of 51%. These studies ruled out clinical heart disease by history, physical examination and ECG with only one study using Mmode echocardiography. All adjusted for cardiovascular risk factor confounders-four analyses also controlled for ischaemia detected on exercise test and nuclear perfusion scan, but no study controlled for LV function. Only one study provided data on LV function. One study examined the correlation of EIPVC complexity and prognosis and found that, after multivariate analysis, it is not an independent risk factor of allcause mortality (no point estimates were provided). None of the studies provided information on EIPVC origin.
In this group, there were six studies and 10 analyses. The total number of patients was 4105, totalling 22 080 patient years of followup. The mean age was 59 years, and the mean sample size was 410 with an average male preponderance of 87%. This group analysed patients who had been referred for an exercise test due to chest pain, exertional dyspnoea, resting ECG abnormalities and exercise capacity assessment as well as postmyocardial infarction patients and heart failure patients. Seven were prospective cohort studies, and one was a retrospective analysis of prospective data. Among these patients, rest PVCs (defined as any PVC on resting ECG during 10 s before exercise) occurred in 0-29% of patients. EIPVC frequency ranged from ≥1 PVC at any time to >7 PVCs at any stage to 10-20% of QRS. All the studies adjusted for confounders using Cox regression and propensity score matching techniques. Only four analyses had echocardiogram data and only two studies adjusted for LV function.
O'Neil et al studied whether EIPVC complexity was associated with poor prognosis, and found that the complexity of EIPVCs was associated with adverse events. Dewey et al studied the effect of EIPVC frequency on its prognostic value, and found that both infrequent and frequent EIPVCs are associated with poor prognosis. No studies provided data on EIPVC origin.
Heterogeneity and publication bias
The I2 statistic for the studies with and without clinical evidence of heart disease was 25 and 44, respectively, indicating only mild to moderate heterogeneity among these studies. The Egger's regression intercepts for studies with and without clinical evidence of cardiac disease were −2.63 (p=0.2) and 1.72 (p=0.12), respectively, suggesting that there was no significant publication bias. Figure 3 shows the funnel plots for patients with and without clinical evidence of heart disease. Figure 3 Funnel plots of the studies categorised by whether or not patients have clinical heart disease. Patients with symptomatic heart disease Go to:
Metaregression and sensitivity analyses
The only study in this group that showed a neutral prognosis for EIPVCs was Bushby et al. Compared to the remaining studies, this was a very small study with short followup and therefore had limited power to pick up the adverse events associated with EIPVCs. Metaregression showed that there was a trend towards the length of study followup being correlated to study outcomes (p=0.06) (figure 4).
Figure 4
Metaregression of mean length of follow up on log or of study outcomes.
Our metaregression showed that none of the study variables-mean age, % male, % with diabetes mellitus, % with hypertension, length of followupcorrelated with endpoints. More importantly, there was no correlation between the percentage of patients with previous myocardial infarction and the percentage of patients with ischaemia on exercise test with study endpoints. The sensitivity analysis showed that: (1) adjustment for LV function and ischaemia detected on exercise test did not affect study outcomes; (2) types of study endpoints did not affect study outcomes either; (3) EIPVCs occurring only during the exercise stage of the exercise test had no prognostic significance; only EIPVCs that occurred during the recovery stage of the exercise test had adverse prognostic value (figure 5). 
Discussion
EIPVCs are common in clinical practice. They are associated with increasing age, male gender, cardiovascular risk factors such as blood pressure and fasting glucose, and structural heart disease.
Despite their prevalence, the optimal management of these arrhythmias is unclear. Studies on the prognostic significance of EIPVCs have produced conflicting results. The studies in the literature are very heterogeneous and include patients ranging from asymptomatic athletes to heart failure patients and postmyocardial infarction patients. Furthermore, many studies did not make adjustment for cardiovascular risk factor confounders. We therefore performed a systematic review and metaanalysis on the longterm prognosis of EIPVCs, excluding studies that did not adjust for cardiovascular risk factor confounders, and separately analysed asymptomatic patients without clinical evidence of heart disease and patients with symptomatic heart disease.
We have shown that EIPVCs are associated with a higher risk of developing cardiovascular events (including nonfatal myocardial infarction, angina, cardiac hospital admissions, cardiac arrest), cardiovascular mortality and all cause mortality over the long term. The risk is elevated both in asymptomatic patients with no clinical evidence of heart disease and in patients with symptomatic heart disease.
One obvious explanation for such an association is that EIPVCs might cause lethal arrhythmia. In Fioretti's study, EIPVCs developed into ventricular fibrillation in a patient requiring defibrillation. This has been reported in 0.05% of exercise tests in the literature which means that 2000 patients need to be exercised to have one event of ventricular fibrillation. Since the mean sample size of our studies is 249 and 410, this cannot fully explain the association of EIPVCs and poor prognosis found in our meta analysis.
Another explanation can be the association of EIPVCs with conditions that by themselves portend poor prognosis. EIPVCs have been associated with LV dysfunction.
Nevertheless, our sensitivity analysis showed that the studies that adjusted for LV function did not find endpoints significantly different from those that did not adjust for LV function. However, as most studies in this metaanalysis did not assess LV function before enrolment, it is certainly possible that some patients with EIPVCs Go to:
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have in fact undiagnosed cardiomyopathies such as hypertrophic cardiomyopathy or arrhythmogenic right ventricular dysplasia which by themselves have poorer prognosis. Similarly, EIPVCs have been associated with ischaemia. Our metaregression showed that the percentage of patients with ischaemia on exercise testing was not correlated with study outcomes, while our sensitivity analysis showed that adjusting for ischaemia detected on exercise testing did not affect study endpoints. In Jouven et al, only 3% of patients positive for ischaemia on exercise testing had EIPVC and, conversely, only 6% of EIPVC patients had a positive test for ischaemia. They found that exercise induced PVCs, independent of ischaemia, were associated with poor prognosis. Thus, another explanation behind the adverse prognostic effect of EIPVCs is needed.
Our metaregression shows that only EIPVCs in the recovery period, not during exercise, were associated with poor prognosis. This suggests that EIPVCs may be a manifestation of autonomic dysregulation which itself has been associated with increased mortality. Ducceschi et al showed that patients with EIPVCs had longer corrected QT intervals at rest and during exercise than patients without EIPVCs. Cole et al showed that decreased vagal reactivation postexercise was associated with increased mortality independent of cardiac risk factors and myocardial perfusion abnormalities. The increased PVC burden in recovery could be due to increased sympathetic drive which itself could create a proarrhythmic substrate with increased conduction and repolarisation heterogeneities. Therefore, autonomic dysregulation may explain the poor prognosis associated with EIPVCs.
Autonomic dysregulation could be a legitimate therapeutic target. This imbalance in autonomic tone can be modulated by pharmacological (eg, βblockade), catheterbased and surgical strategies. Autonomic modulation, whether by pharmacological or catheterbased methods, is an exciting new frontier in electrophysiology. Further studies are required to see if such manipulation can reverse the adverse prognosis associated with EIPVCs.
Study limitations
This metaanalysis is limited by various shortfalls inherent in observational studies, including unknown confounder effects and the inability to infer causality. Studies that have neither been presented nor published are missing. LV function assessment was rare in these studies; therefore patients with ventricular hypertrophy, valvular heart disease or cardiomyopathy may have acted as confounders. In addition, patients with channelopathies could also have acted as possible confounders, although their effect probably is not significant due to their low prevalence. Although our I2 analysis showed freedom from severe heterogeneity, the heterogeneity was moderate and reflects the different demographics of the patients recruited in these studies. Likewise, although there is no significant publication bias, there was a trend towards publication bias in the studies that recruited patients with symptomatic heart disease. Nonetheless, this was adjusted with the Duvell and Tweedie's Trim and Fill method which still showed significant negative prognostic impact of EIPVCs.
Conclusions
EIPVCs, especially those that occur during recovery, are associated with a higher risk of death and cardiovascular events in the long term. This risk is elevated both in asymptomatic patients without evidence of cardiac disease and in patients with symptomatic heart disease. Part of this correlation is due to its association with higher cardiovascular risk profile, cardiac ischaemia and undetected structural heart disease. Autonomic dysregulation may be an additional mechanism behind the poor prognostic effect of EIPVCs. Patients who have EIPVCs warrant further investigations to evaluate the cardiac function and coronary anatomy. If any abnormalities are detected, they should be managed accordingly. Further studies are needed to see whether autonomic manipulation either by pharmacological or catheterbased methods can improve the adverse prognostic effect of EIPVCs.
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